BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alexza Molecular Delivery Corporation (MDC) Changes Name To Alexza Pharmaceuticals, Inc.


10/19/2005 5:12:08 PM

PALO ALTO, Calif., July 21 /PRNewswire/ -- Alexza Molecular Delivery Corporation announced today that it has changed its name to Alexza Pharmaceuticals, Inc. ("Alexza").

"Our name change to Alexza Pharmaceuticals more accurately represents our corporate growth and signals our transition from a primarily research-focused organization to a more advanced stage as we initiate clinical trials for our product candidates," said Thomas B. King, President and CEO. "In mid-2004, we committed ourselves to the goal of placing four product candidates into clinical development by the end of 2005. We remain on track toward achieving this goal."

"In less than five years, Alexza has progressed from a vision and a business plan, to a clinical-stage specialty pharmaceutical company," said Dr. Alejandro Zaffaroni, the Company's Chairman. "This is due to the strength and breadth of Alexza's core technologies, coupled with the profound dedication and effort of our employees. I look forward to great things from this company."

Alexza was co-founded by biotechnology and drug delivery pioneer, Dr. Alejandro Zaffaroni. The Company is developing proprietary products using its core technology, the Staccato(TM) system. This technology enables the rapid onset of therapeutic effect of many small molecule drugs as well as patient self-titration to better treat acute and intermittent conditions. In late 2004, the Company completed its first Phase I clinical study with AZ-001, its initial product candidate and is currently conducting a Phase IIa study with the same product candidate for the treatment of migraine headache. Alexza recently commenced a Phase I study on its second product candidate, AZ-002. Alexza has two additional product candidates in pre-clinical development, with the initiation of Phase I clinical studies for both product candidates targeted for the second half of 2005.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release.

Alexza Pharmaceuticals, Inc.

CONTACT: Thomas B. King, President & CEO of Alexza Pharmaceuticals, Inc.,+1-650-687-3900, or tking@alexza.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES